Cernostics is focused on delivering the next generation of cancer diagnostics & prognostics through a unique approach to tissue analysis.

Learn about our approach...

Barrett's Esophagus & Esophageal Cancer

Three million people in the U.S. have Barrett's Esophagus, a known precursor to esophageal cancer. Until now, identifying which patients are at greatest risk for esophageal cancer has been impossible. Cernostics is looking to change that… Learn how
News
View All News
10/11/2016
New TissueCypher® Validation Study identifies high risk Barrett’s Esophagus patients who are 46x more likely to have cancer at time of biopsy... Read More
08/31/2016
UPMC Partners with Cernostics to Pursue ‘Precision Medicine’... Read More
05/11/2016
Cernostics Announces Scientific Presentations at DDW and ISPOR Meetings Demonstrating Clinical Validation and Cost-Effectiveness of New TissueCypher® Barrett's Esophagus Assay... Read More
Events
01/09/2017 San Francisco, CA
JP Morgan Healthcare Conference
05/06/2017 Chicago, IL
Digestive Disease Week
10/13/2017 Orlando, FL
American College of Gastroenterology
Customer Service

Mon-Fri 9am-5pm (EST)

×